Cutaneous markers of HIV infection

Clinics in Dermatology

Volumn 22, Issue 6, 2004, Pages 487-498

  Rigopoulos, Dimitris ^a   Paparizos, Vasilis ^a   Katsambas, Andreas ^a,b  

^a UNIVERSITY OF ATHENS   (Greece)

^b ANDREAS SYGROS HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTIRETROVIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CANDIDIASIS; CLINICAL FEATURE; CORRELATION ANALYSIS; DERMATOLOGY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE MARKER; EOSINOPHILIA; FOLLICULITIS; HERPES SIMPLEX; HERPES ZOSTER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KAPOSI SARCOMA; LEUKOPLAKIA; PAPULOSIS; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; PRURITUS; PSORIASIS; REVIEW; SEBORRHEIC DERMATITIS; SEROLOGY; SKIN EXAMINATION; SKIN INFECTION; SURVIVAL RATE;

EID: 10944253148     PISSN: 0738081X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clindermatol.2004.07.007     Document Type: Article

References (167)

1. Fauci A.S., Rosenberg Z.F. Immunopathogenesis. Broder S., Merigan T.C., Bolognesi D. Textbook of AIDS medicine. 1994;55-75 Williams & Wilkins, Baltimore
2. Zandman-Goddard G., Shoenfeld Y. HIV and autoimmunity. Autoimmun Rev. 1:2002;329-337
3. Kyriakis K., Tosca A., Katsantonis J., et al. Detection of autoimmunity parameters in the acquired immunodeficiency syndrome (AIDS). Int J Dermatol. 31:1992;113-116
4. Plewing G. Sebohrreic dermatitis. Fitzpatrick T.B., Eisen A.Z., Wolff K.,, et al. Dermatology in general medicine. 4th edition :1993;1569-1574 McGraw-Hill, New York
5. Garman M.E., Tyring S.K. The cutaneous manifestations of HIV infection. Dermatol Clin. 20:2002;193-208
6. Mathes B.M., Douglass M.C. Seborrheic dermatitis in patients with acquired immunodeficiency syndrome. J Am Acad Dermatol. 13:1985;947-951
7. Soeprono F.F., Schinella R.A., Cockerel C.J., et al. Seborrheic-like dermatitis of acquired immunodeficiency syndrome. J Am Acad Dermatol. 13:1986;242-248
8. Hengge U.R., Franz B., Goos M. Decline of infectious skin manifestations in the era of highly active antiretroviral therapy. AIDS. 14:2000;1069-1070
9. Shimizu S., Chen K., Tagami H., et al. Mucocutaneous manifestations in Japanese HIV-positive hemophiliacs. Dermatology. 201:2000;321-325
10. Wang J., Ismail R. Mucocutaneous manifestations of HIV infection a retrospective analysis of 145 cases in a Chinese population in Malaysia. Int J Dermatol. 38:1999;457-463
11. Mirmirani P., Hessol N.A., Murer T.A., et al. Prevalence and predictors of skin disease in the Women's Interagency HIV Study (WIHS). J Am Acad Dermatol. 44:2001;785-788
12. Kaplan M.H., Sadick N., McNutt N.S., et al. Dermatologic findings and manifestations of acquired immunodeficiency syndrome (AIDS). J Am Acad Dermatol. 16:1987;485-506
13. Alessi E., Cusini M., Zerboni R. Mucocutaneous manifestations in patients infected with human immunodeficiency virus. J Am Acad Dermatol. 19:1988;290-297
14. Eisenstat B.A., Wormser G.P. Seborrheic dermatitis and butterfly rash in AIDS. N Engl J Med. 311:1984;189
15. Ippolito F., Passi D., Di Carlo A. Is seborrhoeic dermatitis a clinical marker of HIV disease? Minerva Ginecol. 52:(Suppl 1):2000;54-58
16. Duvic M., Johnson T.M., Rapini R.P., et al. Acquired immunodeficiency syndrome-associated psoriasis and Reiter's syndrome. Arch Dermatol. 123:1987;1622-1632
17. Wolfer L.U., Djemandji-Oudjiel N., Hiletework M., et al. HIV-associated psoriasis. Clinical and histological observations in 36 patients. Hautarzt. 49:1998;197-202
18. Goodman D.S., Teplitz E.D., Wishner A., et al. Prevalence of cutaneous disease in patients with acquired immunodeficiency syndrome (AIDS) or AIDS-related complex. J Am Acad Dermatol. 17:1987;210-220
19. Johnson T.M., Duvic M., Rapini R.P., et al. AIDS exacerbates psoriasis. N Engl J Med. 313:1985;1415
20. Lazar A.P., Roenigk H.H. AIDS and psoriasis. Cutis. 39:1987;347-351
21. Obuch M.L., Maurer T.A., Becker B., et al. Psoriasis and human immunodeficiency virus infection. J Am Acad Dermatol. 275:1992;667-673
22. Morar N., Dlova N., Gupta A.K., et al. Erythroderma a comparison between HIV positive and negative patients. Int J Dermatol. 38:1999;895-900
23. Fischer T., Schworer H., Vente C., et al. Clinical improvement of HIV-associated psoriasis parallels a reduction of HIV viral load by effective antiretroviral therapy. AIDS. 13:1999;628-629
24. Breuer-McHam J.N., Ledbetter L.S., Sarris A.H., et al. Cytokine expression patterns distinguish HIV associated skin diseases. Exp Dermatol. 9:2000;341-350
25. Ortonne N., Ortonne J.P. Psoriasis. Pathogenesis. Presse Med. 28:1999;1259-1265
26. Kuenzli S., Saurat J.H. Peroxisome proliferator-activated receptors in cutaneous biology. Br J Dermatol. 149:2003;229-236
27. Mallon E. Retrovirusus and psoriasis. Curr Opin Infect Dis. 13:2000;103-107
28. Plewig G., Jansen T. Seborrheic dermatitis. Fitzpatrick T.B. Dermatology in general medicine. 5th edition :1999;1482-1497 McGraw-Hill, New York
29. Johnson J.A. Cutaneous manifestations of HIV. Fitzpatrick T.B. Dermatology in general medicine. 5th edition :1999;2505-2538 McGraw-Hill, New York
30. Greenspan J.S., Greenspan D., Lennette E.T., et al. Replication of Epstein-Barr virus within the epithelial cells of oral "hairy" leukoplakia, an AIDS-associated lesion. N Engl J Med. 313:1985;1564-1571
31. Greenspan D., Greenspan J.S., Hearst N.G., et al. Relation of oral hairy leukoplakia to infection with the human immunodeficiency virus and the risk of developing AIDS. J Infect Dis. 155:1987;475-481
32. Itin P., Rufli I., Rudlinger R., et al. Oral hairy leukoplakia in a HIV-negative renal transplant patient a marker for immunosuppression. Dermatologica. 177:1988;126-128
33. Syrjanen S., Laine P., Niemela M., et al. Oral hairy leukoplakia is not a specific sign of HIV infection but related to suppression in general. J Oral Pathol Med. 18:1989;28-31
34. Scully C., Laskaris G., Pindborg, et al. Oral manifestations of HIV infections and their management. I. More common lesions. Oral Surg Oral Med Oral Pathol. 71:1991;158-166
35. Ikediobi N.I., Tyring S.K. Cutaneus manifestations of Epstein-Barr virus infection. Dermatol Clin. 20:2002;283-289
36. Feigal D.W., Katz M.A., Greenspan D., et al. The prevalence of oral lesions in HIV-infected homosexual and bisexual men three San Francisco epidemiological cohorts. AIDS. 5:1991;519-525
37. Eyeson J.D., Tenant-Flowers M., Cooper D.J., et al. Oral manifestations of an HIV positive cohort in the era of highly active anti-retroviral therapy (HAART) in South London. J Oral Pathol Med. 31:2002;169-174
38. Ceballos-Salobrena A., Gaitan-Cepeda L.A., Ceballos-Garcia L., et al. Oral lesions in HIV/AIDS patients undergoing highly active antiretroviral treatment including protease inhibitors a new face of oral AIDS? AIDS Patient Care STDs. 14:2000;627-635
39. Samet J.H., Muz P., Cabral P., et al. Dermatologic manifestations in HIV-infected patients a primary care perspective. Mayo Clin Proc. 74:1999;658-660
40. Patton L.L., McKaig R.G., Strauss R.P., et al. Oral manifestations of HIV in a southeast USA population. Oral Dis. 4:1998;164-169
41. Patton L.L., McKaig R.G., Eron J.J. Jr, et al. Oral hairy leukoplakia and oral candidiasis as predictors of HIV viral load. AIDS. 13:1999;2174-2176
42. Shiboski C.H. Epidemiology of HIV-related oral manifestations in women a review. Oral Dis. 3:(Suppl 1):1997;S18-27
43. Husak R., Garbe C., Orfanos C.E. Oral hairy leukoplakia in 71 HIV-seropositive patients clinical symptoms, relation to immunological status, and prognostic significance. J Am Acad Dermatol. 35:1996;928-934
44. Saag MS. Clinical spectrum of human immunodeficiency virus diseases. In: DeVita VT Jr, Hellman S, Rosenberg SA, editors. AIDS: Etiology, Diagnosis, Treatment and Prevention. 4th edition. Baltimore: Lippincott-Raven, 1997:203-13
45. Birnbaum W., Hodgson T.A., Reichart P.A., et al. Prognostic significance of HIV-associated oral lesions and their relation to therapy. Oral Dis. 8:(Suppl 2):2002;110-114
46. Greenwood I, Zakrzewska JM, Robinson PG. Changes in the prevalence of HIV-associated mucosal disease at a dedicated clinic over 7 years. Oral Dis 1989;8:90-4
47. Greenspan D., Greenspan J.S., Overby G., et al. Risk factors for rapid progression from hairy leukoplakia to AIDS a nested case control study. J Acquir Immune Defic Syndr. 4:1991;652-658
48. Begg M.D., Lamster I.B., Panageas K.S., et al. A prospective study of oral lesions and their predictive value for progression of HIV disease. Oral Dis. 3:1997;176-183
49. Margiotta V., Cambisi G., Mancuso S., et al. HIV infection oral lesions, CD4+ cell count and viral load in an Italian study population. J Oral Pathol Med. 28:1999;173-177
50. Gilson I.H., Barnett J.H., Conant M.A., et al. Disseminated ecthymatous herpes varicella-zoster virus infection in patients with acquired immunodeficiency syndrome. J Am Acad Dermatol. 20:1989;637-642
51. Janier M., Hillion B., Baccard M., et al. Chronic varicella zoster infection in acquired immunodeficiency syndrome. J Am Acad Dermatol. 18:1988;584-585
52. Cohen P.R., Beltrani V.P., Grossman M.E. Disseminated herpes zoster in patients with human immunodeficiency virus infection. Am J Med. 84:1988;1076-1080
53. Jacobson M.A., Berger T.G., Fikrig S., et al. Acyclovir-resistant varicella zoster virus infection after chronic oral acyclovir therapy in patients with the acquired immunodeficiency syndrome (AIDS). Ann Intern Med. 112:1990;187-191
54. Friedman-Kien A.E., Lafleur F.L., Gendler E., et al. Herpes zoster a possible early clinical sign for development of acquired immunodeficiency syndrome in high-risk individuals. J Am Acad Dermatol. 14:1986;1023-1028
55. Buchbinder S.P., Katz M.H., Hessol N.A., et al. Herpes zoster and human immunodeficiency virus infection. J Infect Dis. 168:1993;245
56. Veenstra J., Krol A., van Praag R.M., et al. Herpes zoster, immunological deterioration and disease progression in HIV-1 infection. AIDS. 9:1995;1153-1158
57. Brambilla A.M., Castagna A., Nocita B., et al. Relation between CD4 cell counts and HIV RNA levels at onset of opporunistic infections. J Acquir Immune Defic Syndr. 27:2001;44-48
58. Engels E.A., Rosenberg P.S., Biggar R.J. Zoster incidence in human immunodeficiency virus-infected hemophiliacs and homosexual men, 1984-1997. District of Columbia Gay Cohort Study. Multicenter Hemophilia Cohort Study. J Infect Dis. 180:1999;1784-1789
59. Tappero J.W., Perkins B.A., Wenger J.D., et al. Cutaneous manifestations of opportunistic infections in patients infected with human immunodeficiency virus. Clin Microbiol Rev. 8:1995;440-450
60. Ryder J.W., Croen K., Kleinschmidt-DeMasters B.K., et al. Progressive encephalitis three months after resolution of cutaneous zoster in a patient with AIDS. Ann Neurol. 19:1986;182-188
61. Grant A.D., Fox J.D., Brink N.S., et al. Detection of varicella-zoster virus DNA using the polymerase chain reaction in an immunocompromised patient with transverse myelitis secondary to herpes zoster. Genitourin Med. 69:1993;273-275
62. Gnann J.W. Jr. Varicella-zoster virus atypical presentations and unusual complications. J Infect Dis. 186:(Suppl 1):2002;S91-98
63. Perronne C Lazanas M., Leport C., et al. Varicella in patients infected with the human immunodeficiency virus. Arch Dermatol. 126:1990;1033-1036
64. Melbye M., Grossman R.J., Goedert J.J., et al. Risk of AIDS after herpes zoster. Lancet. 1:1987;728-731
65. Lindan C.P., Allen S., Serufilira A., et al. Predictors of mortality among HIV-infected women in Kigali, Rwanda. Ann Intern Med. 116:1992;320-328
66. Van Griensven G.J., de Vroome E.M., de Wolf F., et al. Risk factors for progression of human immunodeficiency virus (HIV) infection among seroconverted and seropositive homosexual men. Am J Epidemiol. 132:1990;203-210
67. McNulty A., Li Y., Radtke U., et al. Herpes zoster and the stage and prognosis of HIV-1 infection. Genitourin Med. 73:1997;467-470
68. Chaisson R.E., Gallant J.E., Keruly J.C., et al. Impact of opportunistic disease on survival in patients with HIV infection. AIDS. 12:1999;29-33
69. Glesby M.J., Moore R.D., Chaisson R.E. Clinical spectrum of herpes zoster in adults infected with human immunodeficiency virus. Clin Infect Dis. 21:1995;370-375
70. Alliegro M.B., Dorrucci M., Pezzotti P., et al. Herpes zoster and progression to AIDS in a cohort of individuals who seroconverted to human immunodeficiency virus. Italian HIV Seroconversion Study. Clin Infect Dis. 23:1996;990-995
71. Augenbraun M., Feldman J., Chirgwin K., et al. Increased genital shedding of herpes simplex virus type 2 in HIV-seropositive women. Ann Intern Med. 123:1995;845-847
72. Bagdades E.K., Pillay D., Squire S.B., et al. Relationship between herpes simplex virus ulceration and CD4+ cell counts in patients with HIV infection. AIDS. 6:1992;1317-1320
73. Maier J.A., Bergman A., Ross M.G. Acquired immunodeficiency syndrome manifested by chronic primary genital herpes. Am J Obstet Gynecol. 155:1986;756-758
74. Safrin S., Ashley R., Houlihan C., et al. Clinical and serologic features of herpes simplex virus infection in patients with AIDS. AIDS. 5:1991;1107-1110
75. Don P.C., Torakawa J.T., Bitterman S. Herpetic infection mimicking chronic neurotic excoriations in AIDS. Int J Dermatol. 30:1991;136-138
76. Sacks S.L., Wanklin R.J., Reece D.E., et al. Progressive esophagitis from acyclovir-resistant herpes simplex. Clinical roles for DNA polymerase mutants and viral heterogeneity? Ann Intern Med. 111:1989;893-899
77. Connolly G.M., Hawkins D., Harcourt-Webster J.N., et al. Oesophageal symptoms, their causes, treatment, and prognosis in patients with the acquired immunodeficiency syndrome. Gut. 30:1989;1033-1039
78. Norris S.A., Kessler H.A., Fife K.H. Severe, progressive herpetic whitlow caused by an acyclovir-resistant virus in a patient with AIDS. J Infect Dis. 157:1988;209-210
79. Baden L.A., Bigby M., Kwan T. Persistent necrotic digits in a patient with the acquired immunodeficiency syndrome. Herpes simplex virus infection. Arch Dermatol. 127:1991;113-116
80. Glickel S.Z. Hand infections in patients with acquired immunodeficiency syndrome. J Hand Surg. 13:1988;770-775
81. Fangman W.L., Rao C.H., Myers S.A. Hypertrophic herpes simplex virus in HIV patients. J Drugs Dermatol. 2:2003;198-201
82. Gubinelli E., Cocuroccia B., Lazzarotto T., et al. Nodular perianal herpes simplex with prominent plasma cell infiltration. Sex Transm Dis. 30:2003;157-159
83. Erlich K.S., Mills J., Chatis P., et al. Acyclovir-resistant herpes simplex virus infections in patients with the acquired immunodeficiency syndrome. N Engl J Med. 320:1989;293-296
84. Englund J.A., Zimmerman M.E., Swierkosz E.M., et al. Herpes simplex virus resistant to acyclovir. A study in a tertiary care center. Ann Intern Med. 112:1990;416-422
85. Marks G.L., Nolan P.E., Erlich K.S., et al. Mucocutaneous dissemination of acyclovir-resistant herpes simplex virus in a patient with AIDS. Rev Infect Dis. 11:1989;474-476
86. Mosca J.D., Bednarik D.P., Raj N.B., et al. Herpes simplex virus type-1 can reactivate transcription of latent human immunodeficiency virus. Nature. 325:1987;67-70
87. Mosca J.D., Bednarik D.P., Raj N.B., et al. Activation of human immunodeficiency virus by herpesvirus infection identification of a region within the long terminal repeat that responds to a trans-acting factor encoded by herpes simplex virus 1. Proc Natl Acad Sci USA. 84:1987;7408-7412
88. Heng M.C., Heng S.Y., Allen S.G. Co-infection and synergy of human immunodeficiency virus-1 and herpes simplex virus-1. Lancet. 343:1994;255-258
89. Albrecht M.A., DeLuca N.A., Byrn R.A., et al. The herpes simplex virus immediate-early protein, ICP4, is required to potentiate replication of human immunodeficiency virus in CD4+ lymphocytes. J Virol. 63:1989;1861-1868
90. Margolis D.M., Rabson A.B., Straus S.E., et al. Transactivation of the HIV-1 LTR by HSV-1 immediate-early genes. Virology. 186:1992;788-791
91. Ghosh S., Selby M.J., Peterlin B.M. Synergism between Tat and VP16 in trans-activation of HIV-1 LTR. J Mol Biol. 234:1993;610-619
92. Schacker T., Zeh J., Hu H., et al. Changes in plasma human immunodeficiency virus type 1 RNA associated with herpes simplex virus reactivation and suppression. J Infect Dis. 186:2002;1718-1725
93. Mole L., Ripich S., Margolis D., et al. The impact of active herpes simplex virus infection on human immunodeficiency virus load. J Infect Dis. 176:1997;766-770
94. Serrwadda D., Gray R.H., Sewankambo N.K., et al. Human immunodeficiency virus acquisition associated with genital ulcer disease and herpes simplex virus type 2 infection a nested case-control study in Rakai, Uganda. J Infect Dis. 188:2003;1492-1497
95. Suligoi B., Dorrucci M., Uccella I., et al. Italian Seroconversion Study. Effect of multiple herpesvirus infections on the progression of HIV disease in a cohort of HIV seroconverters. J Med Virol. 69:2003;182-187
96. Cooper D.A., Gatell J.M., Kroon S., et al. Zidovudine in persons with asymptomatic HIV infection and CD4+ cell counts greater than 400 per cubic millimeter. The European-Australian Collaborative Group. N Engl J Med. 329:1993;297-303
97. Stein D.S., Graham N.M., Park L.P., et al. The effect of the interaction of acyclovir with zidovudine on progression to AIDS and survival. Analysis of data in the Multicenter AIDS Cohort Study. Ann Intern Med. 121:1994;100-108
98. Youle M.S., Gazzard B.G., Johnson M.A., et al. Effects of high-dose oral acyclovir on herpesvirus disease and survival in patients with advanced HIV disease a double-blind, placebo-controlled study. European-Australian Acyclovir Study Group. AIDS. 8:1994;641-649
99. Suligoi B., Dorrucci M., Volpi A., et al. Italian Seroconversion Study. No protective effect of acyclovir on HIV disease progression in a cohort of HSV-2-HIV-infected individuals. Antivir Ther. 7:2002;289-291
100. Gottlieb M.S., Schroff R., Schanker H.M., et al. Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men evidence of a new acquired cellular immunodeficiency. N Engl J Med. 305:1981;1425-1431
101. Klein R.S., Harris C.A., Small C.B., et al. Oral candidiasis in high-risk patients as the initial manifestation of the acquired immunodeficiency syndrome. N Engl J Med. 311:1984;354-358
102. Yeh C.K., Fox P.C., Ship J.A., et al. Oral defense mechanisms are impaired early in HIV-1 infected patients. J Acquir Immune Defic Syndr. 1:1988;361-366
103. McCarthy G.M. Host factors associated with HIV-related oral candidiasis. A review. Oral Surg Oral Med Oral Pathol. 73:1992;181-186
104. Epstein J.B., Truelove E.L., Izutzu K.T. Oral candidiasis pathogenesis and host defense. Rev Infect Dis. 6:1984;96-106
105. McCarthy G.M., Mackie I.D., Koval J., et al. Factors associated with increased frequency of HIV-related oral candidiasis. J Oral Pathol Med. 20:1991;332-336
106. Powderly W.G. Fungi. Broder S., Merigan T.C., Bolognesi D. Textbook of AIDS medicine. 1994;401-414 Williams & Wilkins, Baltimore
107. Carpenter C.C., Mayer K.H., Fisher A., et al. Natural history of acquired immunodeficiency syndrome in women in Rhode Island. Am J Med. 8:1989;771-775
108. Rhoads J.L., Wright D.C., Redfield R.R., et al. Chronic vaginal candidiasis in women with human immunodeficiency virus infection. JAMA. 257:1987;3105-3107
109. Kumarasamy N., Solomon S., Madhivanan P., et al. Fermatologic manifestations among human immunodeficiency virus patients in South India. Int J Dermatol. 39:2000;192-195
110. Singh A., Thappa D.M., Hamide A. The spectrum of mucocutaneous manifestations during the evolutionary phases of HIV disease an emrging indian scenario. J Dermatol. 26:1999;294-304
111. Phelan J.A., Begg M.D., Lamster I.B., et al. Oral candidiasis in HIV infection predictive value and comparison of findings in injecting drug users and homosexual men. J Oral Pathol Med. 26:1997;137-143
112. Nielsen H., Bentsen K.D., Hojtved L., et al. Oral candidiasis and immune status of HIV-infected patients. J Oral Pathol Med. 23:1994;140-143
113. Ulrich R., Hengge U.R., Franz B., et al. Decline of infectious skin manifestations in the era of highly active antiretroviral therapy. AIDS. 14:2000;1069-1070
114. Smith K.J., Skelton H.G., Yeager J., et al. Cutaneous findings in HIV-1-positive patients a 420-month prospective study. Military Medical Consortium for the Advancement of Retroviral Research (MMCARR). J Am Acad Dermatol. 31:1994;746-754
115. Dodd CL, Greenspan D, Katz MH, et al. Oral candidiasis in HIV infection:peudomembranous and erythematous candidiasis show similar rates of progression to AIDS. AIDS 1991;5(11):1339-43
116. Kaplan J.E., Spira T.J., Fishbein D.B., et al. Ten-year follow-up of HIV-infected homosexual men with lymphadenopathy syndrome evidence for continuing risk of developing AIDS. J Acquir Immune Defic Syndr. 5:1992;565-570
117. Lin R.Y., Goodhart P. The role of oral candidiasis in survival and hospitalization patterns analysis of an inner city hospital human immunodeficiency virus/acquired immune deficiency syndrome registry. Am J Med Sci. 305:1993;345-353
118. Maden C., Hopkins S.G., Lafferty W.E. Progression to AIDS or death following diagnosis with a class IV non-AIDS disease utilization of a surveillance database. J Acquir Immune Defic Syndr. 7:1994;972-977
119. Liautaud B., Pape J.W., DeHovitz J.A., et al. Pruritic skin lesions. A common initial presentation of acquired immunodeficiency syndrome. Arch Dermatol. 125:1989;629-632
120. Zirwas M.J., Seraly M.P. Pruritus of unknown origin a retrospective study. J Am Acad Dermatol. 45:2001;892-896
121. Shapiro R.S., Samorodin C., Hood A.F. Pruritus as a presenting sign of acquired immunodeficiency syndrome. J Am Acad Dermatol. 16:1987;1115-1117
122. Duvic M. Human immunodeficiency virus and the skin selected controversies. J Invest Dermatol. 105:(Suppl 1):1995;117S-121S
123. Hevia O., Jimenez-Acosta F., Ceballos P.I., et al. Pruritic papular eruption of the acquired immunodeficiency syndrome a clinicopathologic study. J Am Acad Dermatol. 24:1991;231-235
124. Milazzo F., Piconi S., Trabattoni D., et al. Intractable pruritus in HIV infection immunologic characterization. Allergy. 54:1999;266-272
125. Skiest D.J., Keiser P. Clinical significance of eosinophilia in HIV-infected individuals. Am J Med. 102:1997;449-453
126. Aires J.M., Rosatelli J.B., De Castro Figueiredo J.F., et al. Cytokines in the pruritic papular eruption of HIV. Int J Dermatol. 39:2000;903-906
127. Muhammad B., Eligius L., Mugusi F., et al. The prevalence and pattern of skin diseases in relation to CD4 counts among HIV-infected police officers in Dar es Salaam. Trop Doct. 33:2003;44-48
128. Boonchai W., Laohasrisakul R., Manonukul J., et al. Pruritic papular eruption in HIV seropositive patients a cutaneous marker for immunosuppression. Int J Dermatol. 38:1999;348-350
129. Soeprono F.F., Schinella R.A. Eosinophilic pustular folliculitis in patients with acquired immunodeficiency syndrome. Report of three cases. J Am Acad Dermatol. 14:1986;1020-1022
130. Buchness M.R., Lim H.W., Hatcher V.A., et al. Eosinophilic pustular folliculitis in the acquired immunodeficiency syndrome. Treatment with ultraviolet B phototherapy. N Engl J Med. 318:1988;1183-1186
131. Rosenthal D., LeBoit P.E., Klumpp L., et al. Human immunodeficiency virus-associated eosinophilic folliculitis. A unique dermatosis associated with advanced human immunodeficiency virus infection. Arch Dermatol. 127:1991;206-209
132. Majors M.J., Cockerell C.J., Cruz P.D. Pruritis in HIV-infected patients an algorithmic approach and review of selected pruritic eruptions. Immunol Allergy Clin North Am. 17:1997;239-251
133. LeBoit P.E., Berger T.G., Egbert B.M., et al. Bacillary angiomatosis the histopathology and the differential diagnosis of a pseudoneoplastic infection in patients with human immunodeficiency virus disease. Am J Surg Pathol. 13:1989;909-920
134. Slater L.N., Welch D.F., Min K.W. Rochalimea henselae causes bacillary angiomatosis and peliosis hepatitis. Arch Intern Med. 152:1992;602-606
135. Plettenberg A., Lorenzen T., Burtsche B.T., et al. Bacillary angiomatosis in HIV-infected patients - an epidemiological and clinical study. Dermatology. 201:2000;326-331
136. Jung A.C., Paauw D.S. Diagnosing HIV-related disease using the CD4 count as guide. J Gen Intern Med. 13:1998;131-136
137. Friedman-Kien A.E. Disseminated Kaposi's sarcoma in young homosexual men. J Am Acad Dermatol. 5:1981;468-471
138. Rappersberger K., Wolff K., Stingl G. Kaposi's sarcoma. Fitzpatrick T.B. Dermatology in general medicine. 4th edition :1993;1244-1256 McGraw-Hill, New York
139. Penn I. The changing pattern of posttransplant malignancies. Transplant Proc. 23:1991;1101-1103
140. Penn I. Kaposi's sarcoma in organ transplant recipients: report of 20 cases. Transplantation 1079;27:8
141. Tebbe B., Mayer daSilva A., Garbe C., et al. Genetically determined coincidence of Kaposi sarcoma and psoriasis in an HIV-negative patient after prednisolone treatment. Spontaneous regression 8 months after discontinuing therapy. Int J Dermatol. 30:1991;114-120
142. Erer B., Angelucci E., Muretto P.D., et al. Kaposi's sarcoma after allogeneic bone marrow transplantation. Bone Marrow Transplant. 19:1997;629-631
143. Chang Y., Cesarman E., Pessin M.S., et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science. 266:1994;1865-1869
144. DiGiovanna J.J., Safai B. Kaposi's sarcoma. Retrospective study of 90 cases with particular emphasis on the familial occurrence, ethnic background and prevalence of other diseases. Am J Med. 71:1981;779-783
145. Friedman-Birnbaum R., Weltfriend S., Katz I. Kaposi's sarcoma retrospective study of 67 cases with the classical form. Dermatologica. 180:1990;13-17
146. Hutt M.S.R. The epidemiology of Kaposi's sarcoma. Antibiot Chemother. 29:1981;3-8
147. Olweny C.L.M. Epidemiological and clinical features of Kaposi's sarcoma in tropical Africa. Friedman-Kien A.E., Laubenstein L.J. AIDS: the epidemic of Kaposi's sarcoma and opportunistic infections. 1984;35-40 Masson Publishing, New York
148. Safai B. Kaposi's sarcoma and Acquired Immunodeficiency Syndrome. In: DeVita VT Jr, Hellman S, Rosenberg SA, editors. AIDS: Etiology, Diagnosis, Treatment and Prevention. 4th edition. Baltimore: Lippincott-Raven, 1997:295-317
149. Elford J., McDonald A., Kaldor J. National HIV Surveillance Committee. Kaposi's sarcoma as a sexually transmissible infection: an analysis of Australian AIDS surveillance data. AIDS. 7:1993;1667-1671
150. Kaldor J.M., Tindall B., Willimson P., et al. Factors associated with Kaposi's sarcoma in a cohort of homosexual and bisexual men. J Acquir Immune Defic Syndr. 6:1993;1145-1149
151. Drew W.L., Mills J., Hauer L.B., et al. Declining prevalence of Kaposi's sarcoma in homosexual AIDS patients paralleled by fall in cytomegalovirus transmission. Lancet. i:1988;66
152. Gates A.E., Kaplan L.D. AIDS malignancies in the era of highly active antiretroviral therapy. Oncology. 16:2002;441-451
153. Lederman M.M., Valdez H. Immune restoration with antiretroviral therapies implications for clinical management. JAMA. 284:2002;236-238
154. Franceschi S., Dal Maso L., Pezzoti P., et al. Incidence of AIDS-defining cancers after AIDS diagnosis among people with AIDS in Italy, 1986-1998. Acquir Immune Defic Syndr. 34:2003;84-90
155. Safai B., Johnson K.G., Myskowski P.L., et al. The natural histoty of Kaposi's sarcoma in the Acquired Immunodeficiency Syndrome. Ann Intern Med. 103:1985;744-750
156. Myskowski P.L., Niedzwiecki D., Shurgot B.A., et al. AIDS-associated Kaposi's sarcoma variables associated with survival. J Am Acad Dermatol. 18:1988;1299-1306
157. Mbulaiteye S.M., Biggar R.J., Goedert J.J., et al. Immune deficiency and risk for malignancy among persons with AIDS. J Acquir Immune Defic Syndr. 32:2003;527-533
158. Brambilla A.M., Castagna A., Nocita B., et al. Relation between CD4 cell counts and HIV RNA levels at onset of opportunistic infections. J Acquir Immune Defic Syndr. 27:2001;44-48
159. Krown S.E., Metroka C., Wernz J.C. Kaposi's sarcoma in the acquired immune deficiency syndrome a proposal for uniform evaluation, response, and staging criteria. AIDS Clinical Trials Group Oncology Committee. J Clin Oncol. 7:1989;1201-1207
160. Hermans P., Lundgren J., Sommereijns B., et al. Survival of European patients with Kaposi's sarcoma as AIDS-defining condition during the first decade of AIDS AIDS in Europe Study Group. AIDS. 11:1997;525-531
161. Brodt H.R., Kamps B.S., Helm E.B., et al. Kaposi's sarcoma in HIV infection: impact of opportunistic infections and survival. AIDS. 12:1998;1475-1481
162. Spano J.P., Salhi Y., Costagliola D., et al. Factors predictive of disease progression and death in AIDS-related Kaposi's sarcoma. HIV Med. 1:2000;232-237
163. Paparizos V.A., Kyriakis K.P., Mileounis K.A., et al. Experience with adriamycin, bleomycin, vincristine (ABV) palliative chemotherapy in advanced AIDS-related Kaposi's sarcoma. J Chemother. 8:1996;403-406
164. Husak R., Mansmann U., Wolfer L.U., et al. Kaposi's sarcoma is an important risk factor for survival in HIV-infected patients independent of CD4+ cell count. AIDS. 13:1999;432-433
165. Paparizos V.A., Kyriakis K.P., Papastamopoulos V., et al. Reponse of AIDS-associated Kaposi sarcoma to highly active antiretroviral therapy alone. J Acquir Immune Defic Syndr. 30:2002;257-258
166. Leitch H., Trudeau M., Routy J.P. Effect of protease inhibitor-based highly active antiretroviral therapy on survival in HIV-associated Kaposi's sarcoma patients treated with chemotherapy. HIV Clin Trials. 4:2003;107-114
167. Tam H.K., Zhang Z.F., Jacobson L.P., et al. Effect of highly active antiretroviral therapy on survival among HIV-infected men with Kaposi sarcoma or non-Hodgkin lymphoma. Int J Cancer. 98:2002;916-922